Abstract
HDACi have shown promising results against a myriad of neurological disorders including AD, HD, PD, SMA, ALS and epilepsy. It is quite evident that in a particular neurological complication, neuronal death or damage is not general, but specific brain regions are particularly affected. Different focal pathologies are exhibited by distinct disorders, and thus gaining insights regarding the region-specific effects of these inhibitors is requisite for targetting correct brain areas. This will subsequently mitigate the toxicity in the normal brain regions.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Agis-Balboa RC, Pavelka Z, Kerimoglu C, Fischer A (2013) Loss of HDAC5 impairs memory function: implications for Alzheimer’s disease. J Alzheimers Dis 33(1):35–44
Basso M, Chen HH, Tripathy D, Conte M, Apperley KYP, De Simone A, Keillor JW, Ratan R, Nebbioso A, Sarno F, Altucci L, Milelli A (2018) Designing dual transglutaminase 2/histone deacetylase inhibitors effective at halting neuronal death. ChemMedChem 13(3):227–230
Ganai SA (2016) Panobinostat: the small molecule Metalloenzyme inhibitor with marvelous anticancer activity. Curr Top Med Chem 16(4):427–434
Ganai SA (2017) Small-molecule modulation of HDAC6 activity: the propitious therapeutic strategy to vanquish neurodegenerative disorders. Curr Med Chem 24(37):4104–4120
Gantt SL, Gattis SG, Fierke CA (2006) Catalytic activity and inhibition of human histone deacetylase 8 is dependent on the identity of the active site metal ion. Biochemistry 45(19):6170–6178
Guan J-S, Haggarty SJ, Giacometti E, Dannenberg J-H, Joseph N, Gao J, Nieland TJF, Zhou Y, Wang X, Mazitschek R, Bradner JE, DePinho RA, Jaenisch R, Tsai L-H (2009) HDAC2 negatively regulates memory formation and synaptic plasticity. Nature 459(7243):55–60
Lobera M, Madauss KP, Pohlhaus DT, Wright QG, Trocha M, Schmidt DR, Baloglu E, Trump RP, Head MS, Hofmann GA, Murray-Thompson M, Schwartz B, Chakravorty S, Wu Z, Mander PK, Kruidenier L, Reid RA, Burkhart W, Turunen BJ, Rong JX, Wagner C, Moyer MB, Wells C, Hong X, Moore JT, Williams JD, Soler D, Ghosh S, Nolan MA (2013) Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group. Nat Chem Biol 9(5):319–325
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Ganai, S.A. (2019). Future Directions. In: Histone Deacetylase Inhibitors — Epidrugs for Neurological Disorders. Springer, Singapore. https://doi.org/10.1007/978-981-13-8019-8_10
Download citation
DOI: https://doi.org/10.1007/978-981-13-8019-8_10
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-13-8018-1
Online ISBN: 978-981-13-8019-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)